20061202
 Barron's Insight: New Drug From Vertex Won't Be the Only Choice   By Alpert, Bill, The Wall Street Journal,  Dec 3, 2006  Future treatments will probably include the drugs of several companies, say hepatitis researchers such as Douglas Dieterich of New York's Mt. Sinai School of Medicine. "One of the things that the business community is really not understanding," says Dr. Dieterich, "is that they think the first drug to market is going to dominate. That's not the case." If he's right, Vertex shares are probably worth closer to $30 than to the $50 to $60 that some bulls see them eventually fetching.   
